

Tibor Kempf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/910115/publications.pdf>

Version: 2024-02-01

88
papers

8,481
citations

53939

47
h-index

51423

90
g-index

95
all docs

95
docs citations

95
times ranked

9808
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Fulminant parvovirus B19 myocarditis after chemotherapy: full recovery after antiviral therapy with tenofovir. <i>Clinical Research in Cardiology</i> , 2022, 111, 233-236. | 1.5 | 5 |
| 2 | Novel self-expanding ALLEGRA transcatheter aortic valve for native aortic stenosis and degenerated bioprosthesis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1234-1242. | 0.7 | 2 |
| 3 | Travelling with heart failure: risk assessment and practical recommendations. <i>Nature Reviews Cardiology</i> , 2022, 19, 302-313. | 6.1 | 7 |
| 4 | Advanced Preconditioning: Impella 5.5 Support for Decompensated Heart Failure Before Left Ventricular Assist Device Surgery. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 189-192. | 0.3 | 3 |
| 5 | Iron supplementation in acute heart failure: energize your life. <i>European Heart Journal</i> , 2021, 42, 3021-3022. | 1.0 | 6 |
| 6 | A mouse model of cardiogenic shock. <i>Cardiovascular Research</i> , 2021, 117, 2414-2415. | 1.8 | 2 |
| 7 | Iron and atherosclerosis: too much of a good thing can be bad. <i>European Heart Journal</i> , 2020, 41, 2696-2698. | 1.0 | 7 |
| 8 | Cardiac iron concentration in relation to systemic iron status and disease severity in non-ischaemic heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 2038-2046. | 2.9 | 32 |
| 9 | Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2000616. | 3.1 | 22 |
| 10 | Inter- and Intracellular Mechanisms of Cardiac Remodeling, Hypertrophy and Dysfunction. <i>Cardiovascular Medicine</i> , 2019, , 39-56. | 0.0 | 1 |
| 11 | Plasma Concentrations of Myeloid-Derived Growth Factor in Healthy Individuals and Patients with Acute Myocardial Infarction as Assessed by Multiple Reaction Monitoring-Mass Spectrometry. <i>Analytical Chemistry</i> , 2019, 91, 1302-1308. | 3.2 | 13 |
| 12 | One-year outcomes with the HeartMate 3 left ventricular assist device. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 662-669. | 0.4 | 38 |
| 13 | Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients. <i>Clinical Research in Cardiology</i> , 2017, 106, 401-410. | 1.5 | 11 |
| 14 | Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. <i>Clinical Chemistry</i> , 2017, 63, 140-151. | 1.5 | 380 |
| 15 | Biomarkers for characterization of heart failure – Distinction of heart failure with preserved and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2017, 227, 272-277. | 0.8 | 49 |
| 16 | An Automated Assay for Growth Differentiation Factor 15. <i>journal of applied laboratory medicine</i> , The, 2017, 1, 510-521. | 0.6 | 35 |
| 17 | Intermediate CD14 ⁺⁺ CD16 ⁺ monocytes decline after transcatheter aortic valve replacement and correlate with functional capacity and left ventricular systolic function. <i>PLoS ONE</i> , 2017, 12, e0183670. | 1.1 | 12 |
| 18 | Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. <i>Lancet</i> , The, 2016, 388, 1903-1911. | 6.3 | 68 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. <i>European Heart Journal</i> , 2016, 38, ehw333. | 1.0 | 115 |
| 20 | Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla® Flex II Occluder. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 217. | 0.7 | 6 |
| 21 | Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. <i>Clinical Chemistry</i> , 2016, 62, 485-493. | 1.5 | 17 |
| 22 | Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. <i>Nature Medicine</i> , 2015, 21, 140-149. | 15.2 | 168 |
| 23 | Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement. <i>American Heart Journal</i> , 2015, 170, 821-829. | 1.2 | 43 |
| 24 | Single coronary artery anomaly with interarterial left main: caught inbetween. <i>European Heart Journal</i> , 2015, 36, 762-762. | 1.0 | 2 |
| 25 | Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. <i>Clinical Chemistry</i> , 2014, 60, 1402-1408. | 1.5 | 24 |
| 26 | Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. <i>International Journal of Cardiology</i> , 2014, 172, 356-363. | 0.8 | 35 |
| 27 | Risk stratification in critically ill patients: GDF-15 scores in adult respiratory distress syndrome. <i>Critical Care</i> , 2013, 17, 173. | 2.5 | 11 |
| 28 | Circulating concentrations of fibroblast activation protein β in apparently healthy individuals and patients with acute coronary syndrome as assessed by sandwich ELISA. <i>International Journal of Cardiology</i> , 2013, 168, 3926-3931. | 0.8 | 22 |
| 29 | Serum hepcidin levels and muscle iron proteins in humans injected with low- or high-dose erythropoietin. <i>European Journal of Haematology</i> , 2013, 91, 74-84. | 1.1 | 23 |
| 30 | Change in Growth Differentiation Factor 15 Concentrations over Time Independently Predicts Mortality in Community-Dwelling Elderly Individuals. <i>Clinical Chemistry</i> , 2013, 59, 1091-1098. | 1.5 | 96 |
| 31 | Incremental Prognostic Value of Biomarkers beyond the GRACE (Global Registry of Acute Coronary) Tj ETQq1 1 0.784314 rgBT /Overload Clinical Chemistry, 2013, 59, 1497-1505. | 1.5 | 50 |
| 32 | Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease. <i>Clinical Chemistry</i> , 2013, 59, 1613-1620. | 1.5 | 91 |
| 33 | Highly Specific Detection of Myostatin Prodomain by an Immunoradiometric Sandwich Assay in Serum of Healthy Individuals and Patients. <i>PLoS ONE</i> , 2013, 8, e80454. | 1.1 | 24 |
| 34 | Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2012, 72, 45-51. | 0.6 | 35 |
| 35 | Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 281-290. | 1.1 | 203 |
| 36 | Identification of Follistatin-Like 1 by Expression Cloning as an Activator of the Growth Differentiation Factor 15 Gene and a Prognostic Biomarker in Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2012, 58, 1233-1241. | 1.5 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. <i>European Heart Journal</i> , 2012, 33, 1095-1104. | 1.0 | 88 |
| 38 | GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery?. <i>European Journal of Heart Failure</i> , 2012, 14, 1191-1193. | 2.9 | 13 |
| 39 | Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. <i>European Journal of Endocrinology</i> , 2012, 167, 671-678. | 1.9 | 134 |
| 40 | Prognostic Utility of Novel Biomarkers of Cardiovascular Stress. <i>Circulation</i> , 2012, 126, 1596-1604. | 1.6 | 414 |
| 41 | Clinical and Genetic Correlates of Growth Differentiation Factor 15 in the Community. <i>Clinical Chemistry</i> , 2012, 58, 1582-1591. | 1.5 | 106 |
| 42 | Growth Differentiation Factor 15 in Heart Failure: An Update. <i>Current Heart Failure Reports</i> , 2012, 9, 337-345. | 1.3 | 95 |
| 43 | Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. <i>Journal of Molecular Medicine</i> , 2012, 90, 353-359. | 1.7 | 48 |
| 44 | Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. <i>Journal of Molecular Medicine</i> , 2012, 90, 361-369. | 1.7 | 57 |
| 45 | Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 203-210. | 1.1 | 138 |
| 46 | Growth Differentiation Factor 15 Plasma Levels and Outcome after Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 2011, 32, 72-78. | 0.8 | 35 |
| 47 | Two vascular arteriovenous malformations with left-to-right shunting and right-heart failure in a single patient. <i>International Journal of Cardiology</i> , 2011, 149, e69-e71. | 0.8 | 0 |
| 48 | Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 872-875. | 0.9 | 350 |
| 49 | A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. <i>Thrombosis Research</i> , 2011, 128, 21-26. | 0.8 | 76 |
| 50 | GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. <i>Nature Medicine</i> , 2011, 17, 581-588. | 15.2 | 411 |
| 51 | GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. <i>Respiratory Research</i> , 2011, 12, 62. | 1.4 | 80 |
| 52 | Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction. <i>Circulation</i> , 2011, 123, 504-514. | 1.6 | 60 |
| 53 | Elevated Plasma Growth Differentiation Factor-15 Correlates with Lymph Node Metastases and Poor Survival in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4825-4833. | 3.2 | 61 |
| 54 | Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. <i>Journal of Clinical Investigation</i> , 2011, 121, 703-714. | 3.9 | 133 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 118, 237-243. | 0.6 | 74 |
| 56 | Growth-Differentiation Factor-15 for Long-Term Risk Prediction in Patients Stabilized After an Episode of Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 88-96. | 5.1 | 82 |
| 57 | Multiple marker approach to risk stratification in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2010, 31, 3024-3031. | 1.0 | 97 |
| 58 | Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure. <i>Circulation</i> , 2010, 122, 1387-1395. | 1.6 | 272 |
| 59 | Improving long-term risk prediction in patients with acute chest pain: The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected nonnecrosis biomarkers. <i>American Heart Journal</i> , 2010, 160, 88-94. | 1.2 | 58 |
| 60 | Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1448-55. | 1.2 | 21 |
| 61 | Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich Assay. <i>Clinical Chemistry</i> , 2009, 55, 1794-1800. | 1.5 | 63 |
| 62 | Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. <i>European Heart Journal</i> , 2009, 30, 2346-2353. | 1.0 | 206 |
| 63 | Circulating and Placental Growth-Differentiation Factor 15 in Preeclampsia and in Pregnancy Complicated by Diabetes Mellitus. <i>Hypertension</i> , 2009, 54, 106-112. | 1.3 | 55 |
| 64 | Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 286-292. | 5.1 | 113 |
| 65 | Growth Differentiation Factor-15: a New Biomarker in Cardiovascular Disease. <i>Herz</i> , 2009, 34, 594-599. | 0.4 | 45 |
| 66 | Growth-Differentiation Factor-15 in Heart Failure. <i>Heart Failure Clinics</i> , 2009, 5, 537-547. | 1.0 | 64 |
| 67 | Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. <i>Blood</i> , 2009, 113, 6707-6715. | 0.6 | 70 |
| 68 | Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. <i>European Heart Journal</i> , 2008, 29, 2327-2335. | 1.0 | 66 |
| 69 | Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. <i>European Heart Journal</i> , 2008, 29, 2851-2858. | 1.0 | 191 |
| 70 | Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 1018-1025. | 2.5 | 158 |
| 71 | Haeme oxygenase promotes progenitor cell mobilization, neovascularization, and functional recovery after critical hindlimb ischaemia in mice. <i>Cardiovascular Research</i> , 2008, 78, 294-300. | 1.8 | 38 |
| 72 | Growth Differentiation Factor-15 in Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 534-541. | 2.5 | 134 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay. <i>Clinical Chemistry</i> , 2007, 53, 284-291. | 1.5 | 245 |
| 74 | Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 2858-2865. | 1.0 | 193 |
| 75 | Growth Differentiation Factor 15 for Risk Stratification and Selection of an Invasive Treatment Strategy in Non-“ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2007, 116, 1540-1548. | 1.6 | 203 |
| 76 | Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non-“ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2007, 115, 962-971. | 1.6 | 327 |
| 77 | Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. <i>American Heart Journal</i> , 2007, 153, 127-132. | 1.2 | 243 |
| 78 | Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1054-1060. | 1.2 | 397 |
| 79 | Anti-Inflammatory Treatment with Standardized Human Serum Protein Solution Reduces Local and Systemic Inflammatory Response after Hemorrhagic Shock. <i>European Surgical Research</i> , 2006, 38, 399-406. | 0.6 | 3 |
| 80 | The Transforming Growth Factor- β 2 Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury. <i>Circulation Research</i> , 2006, 98, 351-360. | 2.0 | 551 |
| 81 | Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 1655-1660. | 3.3 | 143 |
| 82 | Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes. <i>Cardiovascular Research</i> , 2004, 63, 545-552. | 1.8 | 55 |
| 83 | Nitric oxide and the enigma of cardiac hypertrophy. <i>BioEssays</i> , 2004, 26, 608-615. | 1.2 | 46 |
| 84 | Downregulation of Cytoskeletal Muscle LIM Protein by Nitric Oxide. <i>Circulation</i> , 2003, 107, 1424-1432. | 1.6 | 69 |
| 85 | Early albumin infusion improves global and local hemodynamics and reduces inflammatory response in hemorrhagic shock. <i>Critical Care Medicine</i> , 2002, 30, 851-855. | 0.4 | 100 |
| 86 | PLASMA PROTEIN LOSS DURING SURGERY: BENEFICIAL EFFECTS OF ALBUMIN SUBSTITUTION. <i>Shock</i> , 2001, 16, 9-14. | 1.0 | 20 |
| 87 | Cl-esterase-inhibitor Treatment at Early Reperfusion of Hemorrhagic Shock Reduces Mesentery Leukocyte Adhesion and Rolling. <i>Microcirculation</i> , 2001, 8, 427-433. | 1.0 | 30 |
| 88 | Plastic Foil Technique Attenuates Inflammation in Mesenteric Intravital Microscopy. <i>Journal of Surgical Research</i> , 2000, 94, 28-34. | 0.8 | 27 |